Recent News

• 06.09.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.27.2026 - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
• 05.13.2026 - BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
• 05.06.2026 - BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.05.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.04.2026 - BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 144 Report of proposed sale of securities
• 05.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2026 - 144 Report of proposed sale of securities
• 05.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors